|
SMPD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.92705917468584E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.29739577256782E-11 |
| Normal-vs-Stage2 |
2.402300E-03 |
| Normal-vs-Stage3 |
1.55670032420119E-10 |
| Normal-vs-Stage4 |
3.53609999947935E-07 |
| Stage1-vs-Stage2 |
2.597800E-01 |
| Stage1-vs-Stage3 |
2.985600E-01 |
| Stage1-vs-Stage4 |
5.868600E-01 |
| Stage2-vs-Stage3 |
8.674200E-02 |
| Stage2-vs-Stage4 |
1.969760E-01 |
| Stage3-vs-Stage4 |
8.297000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.78732592562392E-12 |
| Normal-vs-AfricanAmerican |
3.229600E-02 |
| Normal-vs-Asian |
1.63239999961817E-07 |
| Caucasian-vs-AfricanAmerican |
8.653700E-02 |
| Caucasian-vs-Asian |
8.588000E-02 |
| AfricanAmerican-vs-Asian |
4.413200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11169999994498E-06 |
| Normal-vs-Female |
1.11088915843993E-12 |
| Male-vs-Female |
3.384200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.9465995482193E-10 |
| Normal-vs-Age(41-60Yrs) |
6.85770329411639E-11 |
| Normal-vs-Age(61-80Yrs) |
1.53641999999232E-05 |
| Normal-vs-Age(81-100Yrs) |
1.030790E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.316400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.662400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.638600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.417000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.452200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.650800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.644000E-04 |
| Classical-VS-Follicular |
1.550800E-01 |
| Classical-VS-Other |
9.219000E-01 |
| Classical-VS-Normal |
2.00990002419132E-09 |
| Tall-VS-Follicular |
1.601890E-04 |
| Tall-VS-Other |
8.613900E-02 |
| Tall-VS-Normal |
4.84445816795187E-12 |
| Follicular-VS-Other |
3.799200E-01 |
| Follicular-VS-Normal |
5.034300E-04 |
| Other-VS-Normal |
4.844400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.47850000020711E-08 |
| Normal-vs-N1 |
2.58819965459622E-10 |
| N0-vs-N1 |
3.362100E-02 |
|
|
